BioNTech (BNTX) shares rose as the company reached a 20-day high, reflecting positive investor sentiment amid its strategic plans.
The company reported €17.2 billion in cash and cash equivalents, enabling it to advance its multi-product oncology strategy by 2026. This includes late-stage programs in immunomodulators, antibody-drug conjugates, and mRNA-based cancer therapies, which are expected to drive significant business growth. Additionally, BioNTech's strategic collaborations aim to enhance its position in the oncology market, ensuring sustainable innovation and meeting increasing demand.
With disciplined R&D spending and a robust financial position, BioNTech is well-positioned to capitalize on growth opportunities in the oncology sector, potentially leading to further advancements in cancer treatment.
Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 141.93 USD with a low forecast of 116.00 USD and a high forecast of 181.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 141.93 USD with a low forecast of 116.00 USD and a high forecast of 181.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
3 Hold
0 Sell
Strong Buy
Current: 106.070
Low
116.00
Averages
141.93
High
181.00
Current: 106.070
Low
116.00
Averages
141.93
High
181.00
Goldman Sachs
Neutral -> Buy
upgrade
$115 -> $142
Al Analysis
2026-01-16
New
Reason
Goldman Sachs
Price Target
$115 -> $142
Al Analysis
2026-01-16
New
upgrade
Neutral -> Buy
Reason
As previously reported, Goldman Sachs upgraded BioNTech to Buy from Neutral with a price target of $142, up from $115. With a broad, strategic suite of programs, the firm views BioNTech as "being at the nexus of significant developments occurring in the oncology field" and uniquely positioned to develop novel-novel combination approaches to transform cancer care, the analyst tells investors. Data unlocks in 2026 could position the company with "a leading foothold in an emerging wave of new product cycles," the analyst added.
Goldman Sachs
Neutral -> Buy
upgrade
$142
2026-01-16
New
Reason
Goldman Sachs
Price Target
$142
2026-01-16
New
upgrade
Neutral -> Buy
Reason
Goldman Sachs upgraded BioNTech to Buy from Neutral with a $142 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BNTX
Unlock Now
Berenberg
Harry Gillis
Buy
maintain
$150 -> $155
2025-12-11
Reason
Berenberg
Harry Gillis
Price Target
$150 -> $155
2025-12-11
maintain
Buy
Reason
Berenberg analyst Harry Gillis raised the firm's price target on BioNTech to $155 from $150 and keeps a Buy rating on the shares.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$136 -> $140
2025-11-10
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$136 -> $140
2025-11-10
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on BioNTech to $140 from $136 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report to reflect lower operating expenses.
About BNTX
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
